October 22, 2007 – Stent thrombosis rates through one year were low for both the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System (0.6 percent, 0.6 percent) and the XIENCE V (PROMUS) Everolimus Eluting Coronary Stent System. (0.8 percent, 1.1 percent), according to results from the SPIRIT III Clinical Trial announced Boston Scientific at TCT 2007.
Analysis of the data was presented by Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation in New York, and the Principal Investigator of the SPIRIT III Trial.

October 22, 2007 - Implantation of the CYPHER Sirolimus-eluting Coronary Stent by Cordis Corp. used to treat completely blocked coronary arteries led to substantial reductions in recurrent blockage and the need for repeat treatment compared to bare metal stents in a study presented today at the Transcatheter Cardiovascular Therapeutics 2007 meeting (TCT 2007).

The HI VISION 5500 fully digital ultrasound system reportedly delivers the latest generation of signal processing technology, sophisticated transducer design and a host of features and options for advanced imaging capabilities across a wide range of clinical situations. The 5500’s electronic architecture incorporates advanced circuit designs optimized for efficiency and function.

October 2007


Ever since the BASKET-LATE study came out suggesting an increase in the rate of death and myocardial infarction in patients treated with drug-eluting stents, the stent market has experienced a mild tremor of its own. Total stent usage has indeed tapered off this year, dropping about 16 percent according to some estimates.*


During the last several decades, the prevalence of Methicillin-Resistant Staphylococus Aureus (MRSA) and other nosocomial infections in U.S. hospitals and medical centers has increased dramatically. According to the Centers for Disease Control and Prevention (CDC), MRSA has climbed from accounting for 25 percent of Staphylococcus Aureus isolates from hospitalized patients in 1990 to almost 60 percent in 2003.

October 18, 2007 - At TCT 2007, Philips Medical Systems is presenting two live interventional cases with the University of Colorado Hospital in Denver, and its integrated cath lab for the interventional care cycle.

October 18, 2007 - This year at TCT ProSolv CardioVascular, a FUJIFILM company and leading provider of enterprise-level image and information management systems, will be highlighting its cardiovascular imaging and information systems (CVIIS).
The ProSolv CardioVascular CVIIS is a reportedly innovative, vendor-neutral and software only solution that allow true integration of all cardiovascular subspecialties.

October 18, 2007 - Abbott announced that trial results for ABSORB, the world’s first clinical trial evaluating the safety and performance of a fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease, are positive.

October 18, 2007 - Combining all of the features of the ACIST CMS and Voyager systems onto one platform, the ACIST CVi Contrast Delivery System for cardiovascular angiographic procedures enhances the ease of contrast and saline injection for physicians, nurses and technicians.

October 18, 2007 - Vascular Solution Inc. spotlights its Guardian hemostasis valve and Gopher Support Catheter at TCT 2007.
The Guardian hemostasis valve uses an ergonomic click-open/click-close design to provide protection during complex interventions and separation of multiple in-dwelling guidewires and other devices used in the catheterization procedure. It also reportedly fits comfortably in the hand and allows for easy one-hand operation.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now